What Determines using Osimertinib in First Line Treatment

What Determines using Osimertinib in First Line Treatment

thoraciconcology

1 year
296 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Tracey L. Evans, MD of the University of Pennsylvania describes what determines using osimertinib in first line treatment. Dr. Evans had two patients newly diagnosed after the FLAURA results came and both of them were given osimertinib in first line. One of them was given afatinib at first, but had toxicity, which justified immediate shift to osimertinib. And, because the FLAURA data is very impressive, she is convinced to use osimertinib in the first line. However, its still not FDA approved. So, for those patients who are already on the earlier generation of the EGFR TKI, like the erlotinib or afatinib, Dr. Evans are not switching them over to osimertinib just because of the FLAURA data. Progression is very important to decide the switch. Doctors can do mutation testing to determine if they have mutations that will not respond to osimertinib or what their resistance mechanism is. Another thing to keep in mind is that, there is a small percentage of patients who develop small-cell transformation on their EGFR TKI therapy. This is another reason to do biopsy. Biopsy at progression can guide doctors and other health practitioners on their next step.
Up Next Autoplay
Long-Term Results from Phase 3 ALTA-1L Trial
Long-Term Results from Phase 3 ALTA-1L Trial
Category: Non-Small Cell Lung Cancer
5 Views
Cancer-News 14 hours
Mount Sinai Receives $1 Million Grant for Prostate Cancer Research
Mount Sinai Receives $1 Million Grant for Prostate Cancer Research
Category: News
2 Views
Cancer-News 15 hours
Treatment-Free Survival, With and Without Toxicity
Treatment-Free Survival, With and Without Toxicity
Category: Kidney Cancer
7 Views
kidneycancer 17 hours
Phase 2 Study of Lenvatinib Plus Pembrolizumab for Disease Progression After PD-1/PD-L1
Phase 2 Study of Lenvatinib Plus Pembrolizumab for Disease Progression After PD-1/PD-L1
Category: Kidney Cancer
0 Views
kidneycancer 18 hours
What's To Come in Modern Imaging Technology
What's To Come in Modern Imaging Technology
Category: Kidney Cancer
3 Views
kidneycancer 1 day
Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia
Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia
Category: Acute Myelogenous Leukemia
4 Views
Cancer-News 1 day
CytoDyn Reports Early Results from First Patient in its Phase 1b/2 CCR5+ Metastatic Triple-Negative Breast Cancer Trial
CytoDyn Reports Early Results from First Patient in its Phase 1b/2 CCR5+ Metastatic Triple-Negative Breast Cancer Trial
Category: Breast Cancer
6 Views
Cancer-News 1 day
Modern Imaging Technology
Modern Imaging Technology
Category: Kidney Cancer
7 Views
kidneycancer 2 days
ASH Releases New Clinical Practice Guidelines on Immune Thrombocytopenia
ASH Releases New Clinical Practice Guidelines on Immune Thrombocytopenia
Category: News
2 Views
Cancer-News 2 days
Management of Clinical Cases in Kidney Cancer
Management of Clinical Cases in Kidney Cancer
Category: Kidney Cancer
7 Views
kidneycancer 3 days